Acton, Massachusetts–based Insulet’s Omnipod 5 significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years old with type 1 diabetes over 12 months of use, according to the company. Earlier this year, the Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S.
The data, collected from a pivotal trial extension, was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans, Louisiana, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.